Tanja Obradovic, Therapeutic Strategy Lead of Oncology at Novotech, Senior Advisor of Oncology Drug Development at HopeAI, shared a post on LinkedIn by Novotech, adding:
“Glad to be moderator discussing needs of APAC-originated innovation during clinical oncology development with two outstanding colleagues and experts Renita Hite and Jiamin Zhuo. Discussion will be around Phase I to Phase III decisions toward creation of assets attractive for (co)development, acquisition and global relevance.
Join us for free webcast: November 3 | 1 PM PT
Register for The Role of APAC in Global Oncology Development.
Since this webcast is happening after ESMO – European Society for Medical Oncology meeting (ESMO2026), we will be glad to comment on any questions that arise from news shared at the meeting. Many APAC-originated assets across numerous trials (Phase I-Phase III) will be reporting data so very timely to brainstorm future state of as one of the topics within this webcast).”
Quoting Novotech:
“Where does APAC add the most value in global oncology development? For sponsors, the answer depends on which markets fit their program, when to involve them, and how they support the broader development strategy.
Join industry experts for a discussion exploring how early strategic decisions around market selection and regulatory pathways can help position an oncology program for global development.
November 3 | 1 PM PT
Register for The Role of APAC in Global Oncology Development.”
Other articles from Tanja Obradovic on OncoDaily.